Is tirzepatide a peptide?

What counts as a peptide

The US National Cancer Institute dictionary defines a peptide as a molecule that contains two or more amino acids, the building blocks of proteins. It adds that peptides containing many amino acids are called polypeptides or proteins ^[11]. The National Human Genome Research Institute’s glossary is more specific: typically 2 to 50 amino acids, with 51 or more counted as a polypeptide ^[14]. At 39 amino acids, tirzepatide sits inside both definitions ^[3].

Many hormones are peptides. GIP, the hormone tirzepatide is modelled on, even carries the word in its name: glucose-dependent insulinotropic polypeptide. GLP-1, the other hormone whose receptor tirzepatide activates, is glucagon-like peptide-1 ^[1].

What the label says about its structure

Section 11 of the Mounjaro® label describes tirzepatide as based on the GIP sequence. It then lists the changes. Positions 2 and 13 hold an amino acid called aminoisobutyric acid (Aib). The end of the chain is an amide. The lysine at position 20 is linked to a 20-carbon fatty diacid through a linker ^[1]. The Zepbound® label gives the same structural description in its own section 11 ^[2].

The label gives the molecular formula C225H348N48O68 and a molecular weight of 4813.53 daltons ^[1]. The Canadian product monograph rounds this to 4,813 daltons and calls tirzepatide an amino acid sequence with a C20 fatty diacid attached ^[4]. For comparison, the Ozempic® label gives semaglutide, another modified peptide, a molecular weight of 4113.58 g/mol ^[9].

Why the fatty acid matters

The label explains one modification directly: the 20-carbon fatty diacid enables binding to albumin, the main protein in blood, and prolongs the half-life. About 99% of tirzepatide in the blood is bound to albumin, and its elimination half-life is about 5 days ^[1].

That is what turns a hormone the body clears quickly into a medicine that can be injected once a week. A 2018 paper by the manufacturer’s scientists, covering laboratory work and phase 1 trials of tirzepatide when it was still called LY3298176, described it as a fatty acid modified peptide designed for once-weekly injection under the skin ^[13]. The label lists the other changes without explaining each one, so this article does not guess at their purpose.

It behaves like a peptide in the body

• It is injected under the skin. The label gives a bioavailability of 80% after subcutaneous injection, and neither US label describes a tablet form ^[1][2].
• It is broken down by cutting the peptide backbone, along with processing of the fatty acid part and the amide. Intact tirzepatide is not found in urine or faeces ^[1]. The European product information describes the same three steps ^[3].
• Because it is an amino acid sequence, the European product information expects any trace in breast milk to be degraded and not absorbed intact by a breastfed infant ^[3]. Whether a medicine suits someone who is breastfeeding is a decision for the prescriber.
• The immune system can recognise it, as the next section shows.

Antibodies, label by label

Peptide and protein medicines can trigger antibodies, and both tirzepatide labels report them in section 12.6. The labels caution that results depend on the test used, so the figures cannot be compared directly with other trials ^[1][2].

Peptide or protein: where US regulators draw the line

Chemistry dictionaries leave the boundary loose, but US law needs a number. The FDA describes peptides as polymers of 40 or fewer amino acids and keeps them out of the “protein” category that, since March 2020, has been regulated as biological products ^[5]. Tirzepatide, at 39 amino acids ^[3], was approved through a standard new drug application, NDA 215866 ^[6].

Not every GLP-1 medicine falls on the same side. Dulaglutide, the active ingredient of Trulicity®, is a fusion protein: two chains, each joining a GLP-1-like sequence to part of a human antibody, made in hamster ovary cells and weighing about 63,000 daltons ^[8]. It was licensed as a biologic under BLA 125469 ^[7]. Our article on approved peptide medicines covers the line in more detail.

Not every GLP-1 medicine is a peptide

Tirzepatide and semaglutide are both modified peptides. Orforglipron, the active ingredient in Foundayo™, is described differently: its label gives a long chemical name and a molecular weight of about 902 g/mol rather than an amino-acid sequence ^[10].

Its label also gives a different profile: a tablet taken once daily with or without food, a bioavailability of 77% after a 0.8 mg dose, and an elimination half-life of about 29 to 49 hours ^[10]. So “GLP-1 medicine” describes what a drug does at the receptor, not what it is made of.

Approved medicine, not a research peptide

Calling tirzepatide a peptide puts it in the same chemical family as peptides sold without FDA approval, but not in the same regulatory category. Mounjaro® and Zepbound® are FDA-approved prescription medicines with labels that set out their uses, doses and warnings ^[1][2].

The FDA warns that unapproved versions of GLP-1 drugs, including tirzepatide, do not go through its review for safety, effectiveness and quality before they are sold. It has warned companies selling tirzepatide labelled “for research purposes” or “not for human consumption” directly to consumers with dosing instructions, and it knows of fraudulent products labelled as compounded tirzepatide, including one linked to a reaction with redness, swelling and a red lump at the injection site ^[12].

Mounjaro®, Zepbound® and Trulicity® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. Ozempic® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Eli Lilly and Company or Novo Nordisk.